Rejuvenate Biomed and SAS use AI for drug repurposing tools

DIEPENBEEK, Belgium and CARY, N.C., Aug. 1, 2024 – Rejuvenate Biomed has announced a collaboration with SAS to create an accessible drug repurposing discovery tool aimed at researchers and scientists. The objective is to uncover medically significant insights about drugs, diseases, and biological networks through a systematic analysis of hidden biological patterns. This tool will be developed on SAS® Viya®, an advanced cloud-native artificial intelligence (AI) and data platform. This partnership merges Rejuvenate Biomed's AI-driven drug discovery capabilities and extensive expertise in drug development with SAS' long-standing experience in AI.

Rejuvenate Biomed's drug discovery tool will leverage the powerful SAS Viya platform. The union of Rejuvenate Biomed’s validated AI-driven drug discovery platform with SAS’ AI expertise aims to facilitate rapid identification of novel biological interactions. The tool will utilize SAS-based analytics to process known biomedical data, implementing algorithms to uncover new insights, and will employ SAS Visual Analytics for reporting purposes. Designed for ease of use, this tool targets bioscience researchers with minimal coding skills but is robust enough to support advanced computational biology teams in developing sophisticated analytical models.

Furthermore, this collaboration will empower Rejuvenate Biomed with the necessary technology to enhance and scale its drug discovery platform, third-party services, and drug development pipeline. 

"Our partnership with SAS strengthens the core strengths of both of our R&D teams," stated Dr. Ann Beliën, Founder and CEO of Rejuvenate Biomed. "Leveraging SAS Viya, we anticipate mitigating risks and expediting the development of our internal portfolio while enhancing our discovery platform and partnership capabilities."

Udo Sglavo, Vice President of Applied AI and Modeling at SAS, remarked, "Our collaboration with Rejuvenate Biomed places us at the vanguard of AI in biomedical research. This partnership reinforces our dedication to supporting innovative AI and analytics through SAS Viya. Rejuvenate Biomed's selection of SAS Viya to advance their proprietary drug discovery engine demonstrates our commitment to providing top-tier AI solutions that improve data analysis efficiency and accelerate the entire drug development lifecycle."

Rejuvenate Biomed is a biotechnology company focused on developing treatments for age-related diseases. It utilizes two proprietary drug discovery platforms, AI-enabled in silico CombinAgeTM and in vivo CelegAgeTM, to build a pipeline of combination drugs targeting various age-related conditions such as neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative diseases. Its leading asset, RJx-01, which is ready for Phase 2 trials, has shown promising results in treating sarcopenia. The company's drug discovery platforms continue to provide valuable insights into future therapeutics, driving pipeline growth and potential partnerships. Based in Belgium, Rejuvenate Biomed is dedicated to promoting healthy aging.

SAS is a global leader in data and AI, helping organizations transform data into actionable decisions with their software and industry-specific solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!